B. Riley Financial Cuts Immunic (NASDAQ:IMUX) Price Target to $27.00

Immunic (NASDAQ:IMUX) had its price target lowered by stock analysts at B. Riley Financial from $40.00 to $27.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s price objective would suggest a potential upside of 105.64% from the stock’s previous close.

Several other analysts have also weighed in on IMUX. Wolfe Research began coverage on shares of Immunic in a research note on Friday. They set an “outperform” rating for the company. Guggenheim initiated coverage on shares of Immunic in a research report on Tuesday, March 24th. They issued a “buy” rating and a $70.00 price target on the stock. Stifel Nicolaus set a $25.00 price target on shares of Immunic and gave the company a “buy” rating in a report on Thursday, April 16th. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Finally, D. Boral Capital lowered shares of Immunic from a “buy” rating to a “hold” rating in a research note on Wednesday, April 15th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immunic has a consensus rating of “Buy” and a consensus target price of $47.57.

Immunic Stock Up 6.7%

NASDAQ:IMUX traded up $0.83 during trading hours on Friday, reaching $13.13. 93,566 shares of the stock were exchanged, compared to its average volume of 327,193. The stock has a market capitalization of $178.83 million, a P/E ratio of -2.35 and a beta of 1.20. The firm has a 50 day simple moving average of $11.40 and a 200-day simple moving average of $8.75. Immunic has a 52 week low of $5.06 and a 52 week high of $15.10.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37). As a group, analysts expect that Immunic will post -4.01 earnings per share for the current year.

Hedge Funds Weigh In On Immunic

Several hedge funds and other institutional investors have recently modified their holdings of IMUX. CTC Alternative Strategies Ltd. bought a new position in shares of Immunic during the first quarter worth about $27,000. Qube Research & Technologies Ltd bought a new stake in Immunic in the 3rd quarter valued at about $29,000. ADAR1 Capital Management LLC bought a new stake in Immunic in the 1st quarter valued at about $33,000. Two Sigma Investments LP acquired a new position in Immunic during the 3rd quarter valued at about $52,000. Finally, Seven Fleet Capital Management LP bought a new position in Immunic in the 4th quarter worth about $83,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.